As biosimilars gain steam, Amgen exec lays out its Humira copycat plans

After about a decade in the biosimilars business, Amgen is among the top players in the burgeoning field. Next year, it's looking to really make its mark with the first U.S. biosim to AbbVie's megablockbuster Humira.